ACTRN12610000621011已完成不适用
Evaluation of Silymarin in prevention of anti tuberculosis drug induced hepatitis in patients newly diagnosed with tuberculosis.
ational Institute of Tuberculosis and Lung Disease (NRITLD)0 个研究点目标入组 60 人开始时间: 2010年7月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •New cases of tuberculosis
排除标准
- •1. Infection with Human Immune deficiency virus
- •2. Infection with hepatitis B virus
- •3. Infection with hepatitis c virus
- •4. Abnormal liver function tests in the base
- •5. Patients treated with the regimens other than Isoniazide, Rifampin, Pyrazinamide.
研究者
相似试验
招募中
不适用
Effect of silymarin in treatment of adverse effects of anti tuberculosis drugs.TuberculosisACTRN12610000643077ational Institute of Tuberculosis and Lung Disease (NRITLD)60
尚未招募
2 期
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
招募中
3 期
Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicityGentamicin-induced renal toxicity in hospitalized patients.Other bacterial diseasesA30-A49IRCT20161010030246N3Shiraz University of Medical Sciences60
招募中
3 期
Protective effect of oral nano-silymarin on vancomycin-induced nephrotoxicity????????????? ???????????.IRCT20200408046990N9Mashhad University of Medical Sciences60
尚未招募
3 期
Evaluating the effectiveness of silymarin in preventing vancomycin nephrotoxicityVancomycin-induced nephrotoxicity in hospitalized patients.Drug- and heavy-metal-induced tubulo-interstitial and tubular conditionsIRCT20161010030246N6Shiraz University of Medical Sciences80